High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy
By: Shannon Y. Chiu, Bhavana Patel, Matthew R. Burns, Joseph Legacy, Aparna Wagle Shukla, Adolfo Ramirez-Zamora, Wissam Deeb and Irene A. Malaty
Open Access
|Feb 2020References
- 1SimpsonDM, HallettM, AshmanEJ, ComellaCL, GreenMW, GronsethGS, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016;86(19):1818–1826. doi: 10.1212/WNL.000000000000256027164716
- 2SimpsonDM, BlitzerA, BrashearA, ComellaC, DubinskyR, HallettM, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70(19):1699–1706. doi: 10.1212/01.wnl.0000311389.26145.9518458230
- 3Botox® (onabotulinumtoxinA). Prescribing Information. Irvine, CA: Allergan, Inc., 2019 Available from: https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/product-prescribing/20190620-BOTOX-100-and-200-Units-v3-0USPI1145-v2-0MG1145.pdf [cited 11 February 2020].
- 4BrinMF Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Muscle Nerve Suppl 1997;6:S208–S220. doi: 10.1002/(SICI)1097-4598(1997)6+<;208::AID-MUS15>3.0.CO;2-19826992
- 5SimpsonDM, AlexanderDN, O’BrienCF, TagliatiM, AswadAS, LeonJM, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996;46(5):1306–1310. doi: 10.1212/WNL.46.5.13068628472
- 6ChildersMK, BrashearA, JozefczykP, RedingM, AlexanderD, GoodD, et al. Dose-dependent response to intramuscular botulinum toxin type a for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004;85(7):1063–1069. doi: 10.1016/j.apmr.2003.10.01515241751
- 7AlbrechtP, JansenA, LeeJ-I, MollM, RingelsteinM, RosenthalD, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology 2019;92(1):e48–e54. doi: 10.1212/WNL.000000000000668830464031
- 8WisselJ, WardAB, ErztgaardP, BensmailD, HechtMJ, LejeuneTM, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009;41(1):13–25. doi: 10.2340/16501977-030319197564
- 9ManciniF, SandriniG, MogliaA, NappiG, PacchettiC A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 2005;26(1):26–31. doi: 10.1007/s10072-005-0378-915877184
- 10BaricichA, GranaE, CardaS, SantamatoA, CisariC, InvernizziM High doses of onabotulinum toxin A in post-stroke spasticity: a retrospective analysis. J Neural Transm (Vienna) 2015;122(9):1283–1287. doi: 10.1007/s00702-015-1384-625724294
- 11BaricichA, PicelliA, SantamatoA, CardaS, de SireA, SmaniaN, et al. Safety profile of high-dose botulinum toxin type A in post-stroke spasticity treatment. Clin Drug Investig 2018;38(11):991–1000. doi: 10.1007/s40261-018-0701-x
- 12WisselJ, BensmailD, FerreiraJJ, MolteniF, SatkunamL, MoraledaS, et al. Safety and efficacy of incobotulinum toxin A doses up to 800 U in limb spasticity the TOWER study. Neurology 2017;88(14):1321–1328. doi: 10.1212/WNL.000000000000378928283596
- 13WisselJ Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity – Insights from recent studies. Toxicon 2018;147:100–106. doi: 10.1016/j.toxicon.2018.01.01829407165
- 14NuanthaisongU, AbrahamN, GoldmanHB Incidence of adverse events after high doses of onabotulinum toxin A for multiple indications. Urology 2014;84(5):1044–1048. doi: 10.1016/j.urology.2014.07.04625443898
- 15Baizabal-CarvalloJF, JankovicJ, PappertE Flu-like symptoms following botulinum toxin therapy. Toxicon 2011;58(1):1–7. doi: 10.1016/j.toxicon.2011.04.01921620881
DOI: https://doi.org/10.5334/tohm.527 | Journal eISSN: 2160-8288
Language: English
Submitted on: Nov 23, 2019
Accepted on: Jan 15, 2020
Published on: Feb 27, 2020
Published by: Columbia University Libraries/Information Services
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2020 Shannon Y. Chiu, Bhavana Patel, Matthew R. Burns, Joseph Legacy, Aparna Wagle Shukla, Adolfo Ramirez-Zamora, Wissam Deeb, Irene A. Malaty, published by Columbia University Libraries/Information Services
This work is licensed under the Creative Commons License.